Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.56 |
| ▸ | TNKS | O95271 | 6/20 | 0.55 |
| ▸ | PARP1 | P09874 | 5/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | GUSB | P08236 | 8/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | TOP2A | P11388 | 1/20 | 0.52 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053518 | 1.00 | CYP1B1 (0.56) | CYP1B1TNKSPARP1TNKS2NPC1 | |
| SCHEMBL346585 | 0.85 | TNKS (0.48) | CYP1B1TNKSPARP1TNKS2GUSB | |
| SCHEMBL122173 | 0.85 | BRD4 (0.45) | CYP1B1TNKSPARP1TNKS2GUSB | |
| SCHEMBL30434203 | 0.85 | BRD4 (0.45) | CYP1B1TNKSPARP1TNKS2GUSB | |
| SCHEMBL348771 | 0.85 | PARP1 (0.48) | CYP1B1TNKSPARP1TNKS2GUSB | |
| SCHEMBL121722 | 0.84 | BRD4 (0.57) | CYP1B1TNKSPARP1TNKS2NPC1 | |
| SCHEMBL30434551 | 0.84 | BRD4 (0.57) | CYP1B1TNKSPARP1TNKS2NPC1 | |
| SCHEMBL146053 | 0.84 | BRD4 (0.54) | TNKSPARP1TNKS2NPC1RAB9A | |
| SCHEMBL30052315 | 0.84 | BRD4 (0.54) | TNKSPARP1TNKS2NPC1RAB9A | |
| SCHEMBL16516162 | 0.82 | TNKS (0.50) | TNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190091235-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2019-03-28 | — | — | US | claimed |
| US-10111885-B2 | Compositions and therapeutic methods for the treatment of complement-associated diseases | RESVERLOGIX CORP. (CA) | 2018-10-30 | — | — | US | claimed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | claimed |
| EP-3268007-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | Resverlogix Corp. (CA) | 2018-01-17 | — | — | EP | claimed |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | RESVERLOGIX CORP (CA) | 2016-12-01 | — | — | US | claimed |
| WO-2016147053-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | RESVERLOGIX CORP. (CA) | 2016-09-22 | — | — | WO | claimed |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2016-09-15 | — | — | US | claimed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | claimed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | claimed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | claimed |
| WO-2013064900-A1 | ORAL IMMEDIATE RELEASE FORMULATIONS FOR SUBSTITUTED QUINAZOLINONES | RESVERLOGIX CORP. (CA) | 2013-05-10 | — | — | WO | claimed |
| US-20130108672-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUBSTITUTED QUINAZOLINONES | RESVERLOGIX CORP. (CA) | 2013-05-02 | — | — | US | claimed |
| US-8114995-B2 | Methods of preparing quinazolinone derivatives | RESVERLOGIX CORP. (CA) | 2012-02-14 | — | — | US | claimed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | claimed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | claimed |
| JP-2011526287-A | — | — | 2011-10-06 | — | — | JP | claimed |
| EP-2346837-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2011-07-27 | — | — | EP | claimed |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2010-01-07 | — | — | US | claimed |
| WO-2009158404-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2009-12-30 | — | — | WO | claimed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | CYP1B1 1292/4885TNKS 4132/4885PARP1 3268/4885 |
| US-20130108672-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUBSTITUTED QUINAZOLINONES | APOB, APOL1, HDLBP | CYP1B1 751/4885TNKS 3955/4885PARP1 3279/4885 |
| US-10111885-B2 | Compositions and therapeutic methods for the treatment of complement-associated diseases | C5, CFH, C1QBP | CYP1B1 2451/4885TNKS 3521/4885PARP1 2459/4885 |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | PCSK9, TGFB1, HMGCR | CYP1B1 4552/4885TNKS 1428/4885PARP1 3204/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | CYP1B1 1292/4885TNKS 4132/4885PARP1 3268/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | CYP1B1 1292/4885TNKS 4132/4885PARP1 3268/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | CYP1B1 1292/4885TNKS 4132/4885PARP1 3268/4885 |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | C5, CFH, C1QBP | CYP1B1 2451/4885TNKS 3521/4885PARP1 2459/4885 |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | APOB, APOL1, LDLR | CYP1B1 993/4885TNKS 2925/4885PARP1 2049/4885 |
| US-20190091235-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | C5, CFH, C1QBP | CYP1B1 2451/4885TNKS 3521/4885PARP1 2459/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | CYP1B1 692/4885TNKS 4229/4885PARP1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.